Literature DB >> 17638802

Improvement of anemia after parathyroidectomy in Chinese patients with renal failure undergoing long-term dialysis.

Tam-Lin Chow1, Tony Tung-Fei Chan, Yiu-Wing Ho, Siu-Ho Lam.   

Abstract

HYPOTHESIS: Most patients undergoing long-term dialysis are anemic because of underproduction of erythropoietin and its inhibition by high parathyroid hormone levels due to secondary hyperparathyroidism. Renal anemia can be improved by parathyroidectomy.
DESIGN: Retrospective cohort study.
SETTING: Regional hospital. PATIENTS: Twenty-three Chinese patients without a previous functioning renal transplant underwent parathyroidectomy for severe secondary hyperparathyroidism in a 3-year period. INTERVENTION: Total parathyroidectomy with or without parathyroid autograft at the forearm. MAIN OUTCOME MEASURES: The preoperative and 6-month postoperative hematological and biochemical variables were compared for any differences by means of a paired t test.
RESULTS: The mean +/- SD follow-up duration was 17.7 +/- 8.1 (range, 6-34) months. Three patients (13%) developed persistent or recurrent hyperparathyroidism and 2 patients (9%) were biochemically hypoparathyroid. The other 18 patients (78%) were euparathyroid. Surgical morbidity was minimal; only 1 patient had complications, consisting of a postoperative fever of unknown origin that resolved with conservative treatment. The mean +/- SD hemoglobin level (8.6 +/- 2.1 vs 9.4 +/- 2.1 g/dL) but not the mean platelet level was significantly (P = .04) increased 6 months postoperatively. Likewise, the following other mean +/- SD biochemical values improved after surgery: parathyroid hormone (2235 +/- 500 vs 151 +/- 312 pg/mL; P<.001), alkaline phosphatase (645 +/- 349 vs 123 +/- 82 U/L; P<.001), calcium (10.8 +/- 4.0 vs 9.3 +/- 1.0 mg/dL; P<.001), phosphate (1.93 +/- 0.73 vs 1.50 +/- 0.51 mmol/L; P = .02), and albumin (3.5 +/- 0.5 vs 3.8 +/- 0.6 g/dL; P = .006).
CONCLUSIONS: Parathyroidectomy is highly effective to control secondary hyperparathyroidism with an exceedingly low complication rate. The hemoglobin level was significantly elevated 6 months postoperatively. The long-term effect warrants future trials.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17638802     DOI: 10.1001/archsurg.142.7.644

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  6 in total

Review 1.  Hyperparathyroidism of Renal Disease.

Authors:  Noah K Yuen; Shubha Ananthakrishnan; Michael J Campbell
Journal:  Perm J       Date:  2016-07-22

Review 2.  Calcium regulation of stem cells.

Authors:  Hans-Willem Snoeck
Journal:  EMBO Rep       Date:  2020-05-17       Impact factor: 8.807

3.  Impact of parathyroidectomy among nondiabetic hemodialysis patients with severe hyperparathyroidism.

Authors:  Qing-Xiu Huang; Jie Pang; Chuan-Ke Shi; Xiao-Wen Huang; Xiao-Fang Chen; Yan-Feng Luo; Hai-Wen An; Jian-Lin Jian; Linna Liu; Yan-Lin Li
Journal:  Ren Fail       Date:  2022-12       Impact factor: 3.222

4.  Association between serum alkaline phosphatase and primary resistance to erythropoiesis stimulating agents in chronic kidney disease: a secondary analysis of the HERO trial.

Authors:  Sunil V Badve; Lei Zhang; Jeff S Coombes; Elaine M Pascoe; Alan Cass; Philip Clarke; Paolo Ferrari; Stephen P McDonald; Alicia T Morrish; Eugenie Pedagogos; Vlado Perkovic; Donna Reidlinger; Anish Scaria; Rowan Walker; Liza A Vergara; Carmel M Hawley; David W Johnson
Journal:  Can J Kidney Health Dis       Date:  2015-08-18

Review 5.  Impact of surgical parathyroidectomy on chronic kidney disease-mineral and bone disorder (CKD-MBD) - A systematic review and meta-analysis.

Authors:  Mugurel Apetrii; David Goldsmith; Ionut Nistor; Dimitrie Siriopol; Luminita Voroneanu; Dragos Scripcariu; Marc Vervloet; Adrian Covic
Journal:  PLoS One       Date:  2017-11-06       Impact factor: 3.240

6.  Impact of Subtotal Parathyroidectomy on Clinical Parameters and Quality of Life in Hemodialysis Patients with Secondary Hyperparathyroidism.

Authors:  Mohamed Mimi Abd Elgawwad El-Kholey; Ghada El Said Ibrahim; Osama Ibrahim Elshahat; Ghada El-Kannishy
Journal:  Endocrinol Metab (Seoul)       Date:  2019-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.